revealed that the overexpression of miR-133a suppressed osteoblast differentiation of bone marrow mesenchymal stem cells and silencing miR-133a resulted in positive effects on glucocorticoid-treated mesenchymal stem cells and on bone loss in glucocorticoid-induced osteoporosis animal models through the MAPK/ERK signaling pathway by targeting FGFR1 (65, 66). The gene discussed is FGFR1; the disease is osteoporosis.